During the past decade, California Liver Research Institute conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 10 clinical trials were completed, i.e. on average, 30.3% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 8 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "California Liver Research Institute" #1 sponsor was "Gilead Sciences" with 9 trials, followed by "Target PharmaSolutions, Inc." with 5 trials sponsored, "Assembly Biosciences" with 2 trials sponsored, "Conatus Pharmaceuticals Inc." with 2 trials sponsored and "Eisai Inc." with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "California Liver Research Institute" #1 collaborator was "ClinIntel" with 1 trials as a collaborator, "Clinical Reference Laboratory" with 1 trials as a collaborator, "DSG EDC" with 1 trials as a collaborator, "Diamond Pharma Services Regulatory Affairs Consultancy" with 1 trials as a collaborator and "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "California Liver Research Institute" are "Nonalcoholic Steatohepatitis" (6 trials), "Hepatocellular Carcinoma" (3 trials), "Liver Diseases" (3 trials), "Primary Sclerosing Cholangitis" (3 trials) and "Carcinoma, Hepatocellular" (2 trials). Many other conditions were trialed in "California Liver Research Institute" in a lesser frequency.

Most popular intervention types in "California Liver Research Institute" are "Drug" (29 trials), "Device" (3 trials), "Other" (2 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "CILO" (2 trials), "Emricasan (5 mg)" (2 trials), "GS-5885 tablet" (2 trials) and "GS-9451 tablet" (2 trials). Other intervention names were less common.

The vast majority of trials in "California Liver Research Institute" are 39 trials for "All" genders.

Currently, there are NaN active trials in "California Liver Research Institute". undefined are not yet recruiting, 9 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in California Liver Research Institute, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in California Liver Research Institute, 1 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".